RETA - Reata Pharmaceuticals, Inc.
| Previous Close | 199.56 |
| Open | 200.00 |
| Bid | 198.90 x 900 |
| Ask | 199.24 x 1100 |
| Day's Range | 196.15 - 201.90 |
| 52 Week Range | 47.50 - 222.33 |
| Volume | 426,984 |
| Avg. Volume | 585,926 |
| Market Cap | 6.584B |
| Beta (3Y Monthly) | 2.63 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.31 |
| Earnings Date | Nov 12, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 278.25 |
- Thomson Reuters StreetEvents
Edited Transcript of RETA earnings conference call or presentation 12-Nov-19 1:00pm GMT
Q3 2019 Reata Pharmaceuticals Inc Earnings Call
- American City Business Journals
Plano-based pharma company expects to double headcount as it raises $505M in stock sale
“I think this is a very exciting phase for the company to transition from the R&D; stage to (becoming) a commercial company,”said Reata's Manmeet Soni in an interview.
- GlobeNewswire
Reata Pharmaceuticals, Inc. Announces Closing of Class A Common Stock Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
The gross proceeds to Reata from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $505.1 million. Citigroup, Jefferies, SVB Leerink and Stifel acted as the joint book-running managers for the offering. Baird, Cantor and Ladenburg Thalmann acted as the co-managers for the offering.
- Simply Wall St.
Reata Pharmaceuticals, Inc. Analysts Are Pretty Bullish On The Stock After Recent Results
A week ago, Reata Pharmaceuticals, Inc. (NASDAQ:RETA) came out with a strong set of third-quarter numbers that could...
- GlobeNewswire
Reata Pharmaceuticals, Inc. Announces Pricing of Upsized Class A Common Stock Public Offering
The offering was upsized to 2,400,000 shares from the original offering size of 2,000,000 shares. The gross proceeds to Reata from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be $439,200,000. The offering is expected to close on November 18, 2019, subject to customary closing conditions.
- GlobeNewswire
Reata Pharmaceuticals, Inc. Announces Proposed Public Offering of Class A Common Stock
Reata Pharmaceuticals, Inc. (RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced its intention to offer and sell 2,000,000 shares of its Class A common stock in an underwritten public offering pursuant to an existing shelf registration statement. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. Citigroup, Jefferies, SVB Leerink and Stifel are acting as the joint book-running managers for the offering.
- Zacks
Reata Pharmaceuticals, Inc. (RETA) Reports Q3 Loss, Tops Revenue Estimates
Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of -5.60% and 5.17%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- Benzinga
The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 11) ACADIA Pharmaceuticals Inc (NASDAQ: ACAD ) Agenus Inc ...
- GlobeNewswire
Reata Pharmaceuticals, Inc. Announces Third Quarter 2019 Financial Results and an Update on Development Programs
PLANO, Texas, Nov. 12, 2019 -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced financial.
- Investor's Business Daily
This Biotech Has Rocketed 181% Since October — Did It Just Tap Out?
Shares of Reata Pharmaceuticals were briefly halted late Monday just before the biotech company confirmed a recently reacquired kidney disease drug succeeded in a Phase 3 study.
- MarketWatch
Reata Pharma kidney drug meets study goals, stock halted
Reata Pharmaceuticals Inc. shares were halted in the extended session Monday as the biotech drug developer reported positive results from a late-stage kidney disease treatment study. Reata shares were flat, following a 1% rise to close the regular session at $213.67. In a Phase 3 study, Reata said its drug bardoxolone treated patients with chronic kidney disease caused by Alport syndrome significantly better than a placebo in primary and secondary endpoints. Alport syndrome is a rare, genetic form of kidney disease that causes end-stage kidney failure in a majority of patients.
- GlobeNewswire
Reata Announces Positive Topline Year One Results From Pivotal Phase 3 Cardinal Study of Bardoxolone Methyl in Patients With Alport Syndrome
Reata Pharmaceuticals, Inc. (RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, announced today that the Phase 3 portion of the CARDINAL study of bardoxolone methyl (bardoxolone) in patients with chronic kidney disease (CKD) caused by Alport syndrome met its primary and key secondary endpoints. After 48 weeks of treatment, patients treated with bardoxolone had a statistically significant improvement compared to placebo in mean estimated glomerular filtration rate (eGFR) of 9.50 mL/min/1.73 m2 (p
- GlobeNewswire
Reata Pharmaceuticals, Inc. to Report Third Quarter 2019 Financial Results and to Provide an Update on Development Programs on November 12, 2019
IRVING, Texas, Nov. 05, 2019 -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that it will report financial results.
- Zacks
Earnings Preview: Reata Pharmaceuticals, Inc. (RETA) Q3 Earnings Expected to Decline
Reata Pharmaceuticals, Inc. (RETA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Insider Monkey
Reata Pharmaceuticals, Inc. (RETA): These Hedge Funds Sold Prior To Large Gains
Concerns over rising interest rates and expected further rate increases have hit several stocks hard during the fourth quarter of 2018. Trends reversed 180 degrees during the first half of 2019 amid Powell's pivot and optimistic expectations towards a trade deal with China. Hedge funds and institutional investors tracked by Insider Monkey usually invest a […]
- Benzinga
The Week Ahead In Biotech: Earnings Trickle In, While Glaxo, Melinta, Foamix And Eton Await FDA Verdict
Biotech stocks saw some strength last week. Positive clinical readouts, a couple of M&A deals and hopes of drug companies clinching a broader opioid settlement agreement worked in favor of the sector. ...
- Zacks
Reata (RETA) Jumps: Stock Rises 5. 6%
Reata (RETA) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
- Benzinga
The Daily Biotech Pulse: Akebia Sues CMS, Roche Raises Guidance Yet Again, Titan Medical Entangled In Credit Crunch
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 15) Celgene Corporation (NASDAQ: CELG ) Eagle Pharmaceuticals ...
- TheStreet.com
Riding 2 Big Winners in Small Biotech
Reata Pharmaceuticals and Axsome Therapeutics each have had a terrific 2019, which helps offset the losing bets in this high-beta sector of the market.
- Zacks
Reata Successfully Completes Neuromuscular Disorder Study
Reata (RETA) rallies following the successful completion of a pivotal study evaluating omaveloxolone as a potential treatment for Friedreich's ataxia, a progressive neuromuscular disorder.
- Investor's Business Daily
How A Recently Reacquired Drug Added $1.8 Billion To This Biotech's Value
Reata Pharmaceuticals soared early Tuesday on positive Phase 2 test results of a treatment for Friedreich's ataxia. The biotech recently reacquired omaveloxolone from AbbVie.
- Benzinga
A Look At Benzinga Pro's Most-Searched Tickers For October 15, 2019
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Synthesis Energy Systems (NASDAQ: SES ) shares ...
- Schaeffer's Investment Research
Reata Pharmaceuticals Options Hot as Shares Skyrocket
The firm's omaveloxolone drug met the main goal of a mid-stage study
- Benzinga
The Daily Biotech Pulse: Reata Leaps On Positive Readout, Takeda Divests, FDA Nod For Akorn, J&J Earnings
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 14.) Natera Inc (NASDAQ: NTRA ) Ra Pharmaceuticals ...
- MarketWatch
Reata stock jumps 30% as neuromuscular disorder drug meets study endpoint
Reata Pharmaceuticals Inc. shares surged after hours Monday as the biotech company announced positive results from a clinical trial for a neuromuscular disorder treatment. Reata shares, which had been halted after hours, surged 33% in the extended session, after closing up 5% at $100.59 in Monday trading for a market cap of just over $3 billion. Compared to placebo, the company said a mid-stage study of its treatment omaveloxolone significantly improved symptoms of Friedreich's ataxia, a debilitating neuromuscular disease that results in loss of coordination, weakness and fatigue. There are currently no treatments approved by the Food and Drug Administration for the disease, which affects about 22,000 globally, the company said.
